Christophe Lurquin

Immunology and Microbiology · Life Sciences

33h-index10.9kcitations70works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(49), T-cell and B-cell Immunology(23), vaccines and immunoinformatics approaches(20), Glycosylation and Glycoproteins Research(18), Monoclonal and Polyclonal Antibodies Research(14)

Publications70 total

Supplementary Table 1 from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Supplementary References from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Supplementary Figure Legends 1-3 from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Supplementary Figures 1-3 from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Data from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Supplementary Methods from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Supplementary Table 1 from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Supplementary References from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Supplementary Methods from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Supplementary Figures 1-3 from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Supplementary Figure Legends 1-3 from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Data from A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
2023Open Access
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes
Nature Communications·2017· 215 citedOpen Access
A new transcript in the <i>TCRB</i> locus unveils the human ortholog of the mouse pre‐<i>Dß1</i> promoter
Immunity Inflammation and Disease·2017Open Access
Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy
Proceedings of the National Academy of Sciences·2014· 3 citedOpen Access
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Cancer Research·2011· 174 citedOpen Access
A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
Cancer Research·2010· 175 cited
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
PubMed·2007· 134 cited
Monitoring Mage Vaccination. Insights Into Mechanisms of Tumor Regression
Journal of Immunotherapy·2005
Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen
The Journal of Experimental Medicine·2005· 239 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Thierry Boon(42), Etienne De Plaen(24), Pierre van der Bruggen(17), Bernard Lethé(16), Pierre G. Coulie(14), Aline Van Pel(14), Charles De Smet(13), Jean‐Pierre Szikora(10), Francis Brasseur(9), Patrick Chomez(7), Nicolas van Baren(7), Catia Traversari(6), Vincent Brichard(5), Olivier De Backer(5), Benoı̂t J. Van den Eynde(5), Kris Thielemans(5), Thomas Wölfel(4), Jean‐Christophe Renauld(4), Vaios Karanikas(4), Didier Colau(4)